Cartesian Therapeutics
Manufacturing · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7495 New Horizon Way, Frederick, Marylan...Phone Number
(301) 348-8698Revenue
<$5 MillionStock Symbol
RNACIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Explore more
Cartesian Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cartesian Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cartesian Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Cartesian Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Cartesian Therapeutics
Click to see if Cartesian Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Cartesian Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Cartesian Therapeutics has new funding data
Earning: See what the market has to say on Cartesian Therapeutics recently announced quarterly report
Check if Cartesian Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Cartesian Therapeutics
Find 2 more new buyers
Compare Similar Companies to Cartesian Therapeutics
Compare insights from companies similar to Cartesian Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cartesian Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cartesian Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cartesian Therapeutics.
Cartesian Therapeutics financials insights
Gather financial insights about Cartesian Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$130M
Cartesian Therapeutics Tech Stack
A closer look at the technologies used by Cartesian Therapeutics
Most Recent Scoops
Person-Based
Partnership, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Person-Based
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Cartesian Therapeutics News & Media
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stCartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On June 8, 2026, the Company issued to this employee an option to purchase an aggregate of 6,100 shares of the Company’s common stock with an exercise price of $5.86, the closing trading price of the Company’sCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cartesian Therapeutics
Sign Up For FreeTo access detailed company insights
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as... Read More
